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           One of the characteristics of type 2 diabetes mellitus (T2DM) is the state 
of persistent oxidative stress (OS) that has been implicated in the pathogenesis 
of diseases such is atherosclerosis mainly through chronic hyperglycemia that 
stimulates production of reactive oxygen species (ROS) and increases OS.  
Glutathione S-transferase P1 (GSTP1) is a member of the cytosolic 
GST superfamily. It plays an important role in neutralizing OS as an enzyme. 
Also, it participates in regulation of stress signaling and protects cells against 
apoptosis via its noncatalytic ligand-binding activity. GSTP1 Ile105Val 
functional polymorphism influences protein catalytic activity and stability and 
the aim of this study was to determine whether this gene variation influences 
susceptibility to atherogenesis in T2DM patients.  
A total of 240 individuals (140 patients with T2DM, accompanied with 
clinical manifestations of atherosclerosis, and 100 healthy controls) were 
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included in this study. Genomic DNA was isolated from peripheral blood cells 
and genotyping was performed using polymerase chain reaction followed by 
restriction fragment length polymorphism (PCR-RFLP) analysis.  
We obtained no statistically significant differences in the distribution of alleles 
and genotypes between cases and controls (P>0.05) but association between 
Ile/Val (OR=0.6, 95%CI=0.35-1.05, P=0.08) and Val/Val (OR=0.45, 
95%CI=0.18-1.11, P=0.08) genotypes and disease approached significance 
(P=0.08).  
Our results indicated that a larger study group is needed to establish the true 
relationship between potentialiy protective allele Val and the disease, and to 
determine the influence of other GSTP1 polymorphisms on atherogenesis in 
T2DM patients. 
Key words: GlutathioneS-transferase P1, gene polymorphism, type 2 
diabetes mellitus, atherosclerosis 
 
INTRODUCTION 
Diabetes is one of the most frequent chronic diseases and it is a major public health 
problem worldwide. Serbia belongs to the group of European countries with the highest diabetes 
mortality rates where diabetes is the fifth leading cause of death and the fifth cause of the burden 
of disease. The number of deaths is even higher because of the errors in coding the causes of 
death particulary in those who died from myocardial infarction, stroke or other microvascular 
and macrovascular long term comlications. At least a half of the persons, especially elderly, with 
type 2 diabetes mellitus (T2DM) have not been diagnosed and are not aware of their disease  
until mainly cardiovascular and renal complications are already present (INSTITUTE OF PUBLIC 
HEALTH OF SERBIA "DR MILAN JOVANOVIĆ BATUT, 2011). Diabetes prevalence grows with age 
and ageing is associated with decrease in insulin secretion, action and clearance even in non-
obese healthy elderly subjects (STEVIC et al. 2007). 
As the result of diabetes there is a state of increased oxidative stress (OS) that leads to 
the development of accelerated atherosclerosis. Chronic hyperglycemia stimulates reactive 
oxygen species (ROS) production and increases oxidative stress. Excessive generation of ROS, 
such as superoxide, hydrogen peroxide and hydroxyl radical, along with reactive nitrogen species 
(RNS) such as nitric oxide, oxidize DNA, proteins and other cellular components leading to their 
damage (PITOCCO et al. 2010; KANETO et al. 2010; PEREIRA et al. 2008). Studies have shown that 
individuals with lowered antioxidant capacity are at increased risk of T2DM (BAYNESS and 
THORPE, 1999; GALLOU et al. 1993).  
Among candidate genes related to OS, genes for cytosolic glutathione S-transferases 
(GSTs), especially mu (GSTM1), theta (GSTT1) and pi (GSTP1) are intensively studied. 
Although these cytosolic GSTs detoxify cytotoxic agents and protect cellular macromolecules 
catalyzing the conjugation of electrophilic compounds with glutathione (GSH), the role of GSTs 
in catalyzing the conjugation with endogenous products of oxidative damage to lipids (acrolin, 
crotonaldehyde, 4-hydroxynonenal) and DNA (base propenals) is well established (BERHANE et 
al. 1994). At physiological concentrations, GSTs regulate ROS levels influencing cellular 
proliferation and preventing ROS accumulation (HAYES and MCLELLAN, 1999) and thereby 
every change in GSTs genes can lead to oxidative stress.  
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Glutathion S-transferase P1 (GSTP1) is a member of the cytosolic GST superfamily 
(COWELL et al. 1988; MANNERVIK and DANIELSON, 1988). Because of its enzymatic and 
nonenzymatic multiple roles (WANG et al. 2001; HOLLEY et al. 2007) variation in the expression 
and activity of GSTP1 has been associated with a variety of human diseases (HARRIES et al.1997; 
MATTHIAS et al. 1998; MCILWAIN et al. 2006; NIKOLIĆ et al. 2011; SUVAKOV et al. 2012; AMER et 
al. 2012; GÖNÜL et al. 2012; KARIŽ et al. 2012; SANTL LETONJA et al. 2012; GRUBISA et al. 
2012). 
GSTP1 is genetically polymorphic and two common nonsynonymous single nucleotide 
polymorphisms (SNPs) (Ile105Val and Ale114Val) and the methylation state of a CpG islands in 
its promoter have been studied extensively. The Ile105Val genotype constitutes an A313G 
change causing an Ile to Val substitution at amino acid 105 within the active site of the enzyme 
which results in substantial reduction of enzyme activity by altering its catalytic activity 
(TOWNSEND and TEW, 2003).  
Since the susceptibility to OS is partially determined by genetic background there has 
been a deep interest in discovering additional genetic variants as markers of OS, which may have 
a role in predicting risk of oxidative stress-based diseases. So, in the present study we have 
evaluated possible interactions between GSTP1 Ile105Val gene polymorphism and clinical 
manifestations of atherosclerosis in type 2 diabetes mellitus patients from Serbia. 
 
MATERIALS AND METHODS 
The study comprised of 140 patients with T2DM and clinical manifestations of 
atherosclerosis (86 males and 54 females, age 40-70 years) treated at Dedinje Cardiovascular 
Institute and Zvezdara University Medical Center, Belgrade, Serbia from 2010-2011. The control 
group was composed of 100 healthy individuals, age and sex matched with cases. Participants 
were not related and originated from different parts of Serbia and only those who have signed the 
informed consent have been included in the study. The study was approved by the ethical 
Committee of Zvezdara University Medical Center.  
All patients had diagnostic criteria for diabetes based on subsequent values of glycemia 
(2 values of glycemia in 2 subsequent days): fasting plasma glucose concentration ≥7,0 mmol/L 
(126 mg/dL) or glycemia in any random blood sample (regardless of meals) ≥ 11,1 mmol/L (200 
mg/dL) with the presence of typical diabetes symptoms (polyuria, polydipsia, weight loss) or 
based on the value of glycemia during an Oral Glucose Tolerance Test (OGTT): plasma glucose 
concentration during an OGTT in the 120th minute ≥ 11,1mmol/L (200 mg/dL) ((INSTITUTE OF 
PUBLIC HEALTH OF SERBIA "DR MILAN JOVANOVIĆ BATUT, 2011). Diagnosis of atherosclerosis was 
based on medical and familiy history, physical exam, blood test and some of noninvasive and 
invasive test-methods (echocardiogram, ankle/brachial index, stress testing, computed 
tomography scan, angiography) or according to anamnesis data about: lower extremity arterial 
surgery, carotid artery surgery, previous myocardial infarction, previous cerebro-vascular 
diseases, vascular dementia, angina.  
Genomic DNA was extracted from peripheral blood cells by DNeasy Blood & Tissue 
Kit (Qiagen, GmbH, Germany), and isolated DNA was stored at +4 °C until further analysis. 
GSTP1 Ile105Val genotyping was performed using polymerase chain reaction-
restriction fragment length polymorphism (PCR-RFLP) method as previously described 
(HARRIES et al. 1997). A 176bp PCR products were digested by Alw26 restriction enzyme (MBI 
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Fermentas, Lithuania) according to manufacturers recommendations. Digestion products were 
separated on 3 % agarose gel, stained with ethidium bromide (0.5 µg/mL) and visualized under 
UV light for genotype determination. The absence of restriction site indicated wild type (WT) 
genotype Ile/Ile (176bp), and presence of restriction site resulting in two fragments 91bp and 85 
bp indicated mutant genotype Val/Val. 
Statistical analysis was carried out using SPSS software (version 17). Allele and 
genotype frequencies in cases and controls were compared using chi-square test (Χ2 test) and the 




The allele and genotype frequency distribution for the GSTP1 Ile105Val polymorphism in 
T2DM patients with clinical manifestations of atherosclerosis and controls are given in Table 1.  
Low-activity (Val) allele was more frequent in the control group (38.5%) compared to 
cases (32%) and heterozygotes Ile/Val and homozygotes Val/Val genotypes frequencies were 
higher in controls than in patients (55% versus 45% for Ile/Val and 11% versus 9.3% for 
Val/Val), the difference however did not reach statistical significance between groups (P>0.05).  
Similarly, none of the values obtained by logistic regression analysis showed a statistical 
significance though Val allele (OR=0.7, 95%CI=0.5-1.8, P=0.13), Ile/Val (OR=0.6, 
95%CI=0.35-1.05, P=0.08) and Val/Val (OR=0.45, 95%CI=0.18-1.11, P=0.08) genotypes 
showed 1.43, 1.67 and 2.22 fold decrease in risk of disease, respectively. Also, grouped 
genotypes Ile/Val+Val/Val showed a nonsignificant 1.37 fold decrease in risk (OR=0.73, 
95%CI=0.43-1.25, P=0.26) in compare with reference Ile/Ile (Table 1). 
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The most of diabetes-related deaths and complications are due to cardiovascular 
diseases. As a result of diabetes, there is a state of increased oxidative stress and compromised 
antioxidant defense that leads to the development of accelerated atherosclerosis and both 
microvascular and macrovascular long-term complications.  
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Excess mortality from coronary heart disease (CHD) among diabetic people compared 
to the general population has been demonstrated (HUXLEY et al. 2006). Cross-sectional study of 
657 consecutive patients with symtomatic carotid atherosclerotic disease from our population 
showed that half of these patients have features of the metabolic syndrome (55.6% of studied 
patients) (MAKSIMOVIC et al. 2009). Patients with premature atherosclerosis (≤ 50 years of age) 
more frequently had 4 and 5 risk factors for atheosclerosis and DM is among the most significant 
for atherosclerotic disease of the supra-aortic branches. In patients with coronary artery disease 
(CAD), DM is a less prevalent risk factor in patients with premature coronary disease compared 
with elderly (RADAK et al. 2012). 
In the present case-control study we have investigated the association of GSTP1 
Ile105Val with cardiovascular complications in state of increased oxidative stress. According to 
our results there are no statistically significant differences in the distribution of alleles and 
genotypes for the GSTP1 Ile105Val polymorphism between cases and controls, which is in 
accordance with the results of some other similar studies (GÖNÜL et al. 2012; SANTL LETONJA et 
al. 2012; KARIŽ et al. 2012; MOASSER et al. 2012).  
Though this GSTP1 gene polymorphism has been widely studied in malignant diseases 
and many previous studies reported the association between Val with a variety of human cancers 
(HARRIES et al.1997; MATTHIAS et al. 1998; MCILWAIN et al. 2006; NIKOLIĆ et al. 2011), 
controversial results have been reported so far about the importance of this allele in oxidative 
stress-based diseases (FRYER et al. 2000; MATTEY et al. 1999; ISHII et al. 1999; MANN et al. 2000; 
SUVAKOV et al. 2012; AMER et al. 2012; GÖNÜL et al. 2012; KARIŽ et al. 2012; SANTL LETONJA et 
al. 2012; RAMPRASATH et al. 2011; BID et al. 2010; GRUBISA et al. 2012).  
The controversial results obtained by studies of different populations might be 
atribbuted to the interaction of many factors, such as differences in ethnic background and 
differential susceptibility to diseases. Our study confirmed previously reported results from other 
studies from Serbia reporting effects of GSTP1 Ile105Val polymorphism on T2DM in patients 
with pancreatic disease (NIKOLIĆ et al. 2011), on oxidative stress in haemodialysis patients, 
including patients with diabetic nephropathy (SUVAKOV et al. 2012), and effects of this 
polymorphism on patients with clinical manifestations of atherosclerotic disease without T2DM 
(GRUBISA et al. 2012).  
Our results showed statistically nonsignificant decrease in the risk of atherosclerosis for 
allele Val and genotypes Ile/Val and Val/Val, but the association between these two genotypes 
and disease approached significance (P=0.08). Similar results have been reported in patients with 
manifest atherosclerotic disease (GRUBISA et al. 2012) and in the study on rheumatoid arthritis 
(MATTEY et al. 1999). In a study performed by Fryer and coworkers (FRYER et al. 2000), authors 
found that the Val1/Val genotype conferred a 6-fold decrease in asthma risk and that this 
genotype correlated with decreased severity of airway hyperresponsiveness (AHR). Mann et al 
(MANN et al. 2000) found that GSTM3 AA and homozygosity for both GSTM1*0 and the GSTP1 
Ile were linked with severe disability in multiple sclerosis (MS) and association between Ile and 
chronic obstructive pulmonary disease (COPD) was also found (ISHII et al. 1999).  
GSP1 performs as a phase II detoxification enzyme. Also, it participates in regulation of 
stress signaling and protects cell against apoptosis via its noncatalytic ligand-binding activity 
(HOLLEY et al. 2007). In low levels of OS or unstressed conditions GSTP1 is found catalytically 
active and it is an inhibitor of c-Jun-N-terminal kinase (JNK) (ADLER et al. 1999). Exposure to 
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higher levels of OS causes GSTP1 dissociation from GSTP1-JNK complexes and JNK 
activation. This activates signalling pathways for stress response and apoptosis, and GSTP1 
forms covalently linked and enzymatically inactive dimers and oligomers (TEW and RONAI, 
1999). Some studies suggested that suppression of GSTP1 leads to elevated JNK activity, 
increased proliferation and reduced apoptosis (RUSCOE et al. 2001). Also, oxidative stress causes 
activation of transcription factor nuclear factor-kappa B (NF-kB) that induces expression of NF-
kB responsive genes including GSTP1 (XIA et al. 1996), while GSTP1 expression rises in 
response to OS or proinflammatory stimuli. 
When the expression of GSTP1 decreases or protein has low activity, it has been 
speculated that cell becomes more susceptible to mutation and damage as a result of exposure to 
electrophiles and oxidative stress (KINZLER and VOGELSTEIN, 1997). It has been assumed that 
genetic variation is responsible for alteration in the level of enzyme activity as a result of at least 
two mechanisms-changes in the active site (Ile to Val substitution in the hydrophobic substrate 
binding site), and differences in levels of enzyme protein (MOYER et al. 2008). Probably, 
alteration of only one or two amino acids as a result of genetic polymorphism can be associated 
with drastic changes in the level of protein often due to rapid protein degradation through a 
ubiquitin-proteasome-mediated process (WANG et al. 2003; WEINSHILBOUM and WANG, 2004). In 
studies on GSTP1 gene sequence variation and functional genomic, about 35 SNPs have been 
identified and some of them are uncaracterized yet. Authors showed that the variant nucleotide at 
(-18) resulted in protein binding that was not observed in WT sequence. Because this functional 
SNP is tighly linked with Ile105Val it is possible that a portion of the association of the codon 
105 polymorphism with various clinical phenotypes may result from the effect of transcription of 
G(-18)A SNP (MOYER et al. 2008). We evaluated only one polymorphism in polymorphic 
GSTP1 that probably limited this association study. 
Although our data provide evidence that Ile105Val polymorphism is not associated with 
increased oxidative stress in T2DM and atherogenesis, a larger study group is needed to establish 
true relationship between potentialy protective allele Val and individual susceptibility to disease 
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Jedna od osobina tipa 2 dijabetes mellitus (T2DM) je stanje perzistentnog oksidativnog 
stresa (OS) koji je sastavni deo patogeneze bolesti kao što je ateroskleroza i to najčešće putem 
hronične hiperglikemije koja stimuliše nastanak reaktivnih vrsta kiseonika (tzv ROS) i povećava 
nivo OS.  
 Glutation S-transferaza P1 (GSTP1) pripada superfamiliji citosolnih GST. Kao enzim, 
ima važnu ulogu u neutralizaciji OS. Takođe, učestvuje u regulaciji signalnog puta stresa ali i 
štiti ćelije od apoptoze putem nekatalitičke ligand-vezujuće aktivnosti. Funkcionalni 
polimorfizam Ile105Val GSTP1 gena utiče na katalitičku aktivnost proteina i na njegovu 
stabilnost i cilj ove studije je bio da se utvrdi da li ova genska varijanta utiče na osetljivost na 
aterogenezu kod pacijenata sa T2DM.  
Ukupno 240 osobe (140 pacijenata sa T2DM i nekom od kliničkih manifestacija 
ateroskleroze i 100 zdravih kontrola) je bilo uključeno u ovu studiju. Genomska DNK je 
izolovana iz ćelija periferne krvi a genotipizacija je urađena primenom reakcije lančane 
polimeraze posle koje je urađena analiza dužine restrikcionih fragmenata (PCR-RFLP analiza). 
Nismo dobili statistički značajne razlike u raspodeli alela i genotipova između obolelih i 
kontrola (P>0.05) ali asocijacija između Ile/Val (OR=0.6, 95%CI=0.35-1.05, P=0.08) i Val/Val 
(OR=0.45, 95%CI=0.18-1.11, P=0.08) genotipova i bolesti se približila značajnosti (P=0.08). 
Naši rezultaati pokazuju da je potrebna veća grupa ispitanika da bi se utvrdila prava 
veza između potencijalno protektivnog alela Val i bolesti kao i da bi se utvrdio uticaj drugih 
polimorfizama gena GSTP1 na aterogenezu kod T2DM pacijenata. 
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